ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • About
  • News
  • FDA Approves AVYCAZ for serious gram negative infections

FDA Approves AVYCAZ for serious gram negative infections

28 Feb 2015 6:21 AM | Kristi Kuper

On February 25, 2015, The U.S. Food and Drug Administration approved Avycaz (ceftazidime-avibactam) to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.Avycazis a fixed-combination drug containing ceftazidime and avibactam, a new beta-lactamase inhibitor.


See for more info.

Society of Infectious Diseases Pharmacists •  403 W. Saint Charles, Suite B, Lombard, IL 60148
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software